简介：Paediatricretinaldetachment(PRD)isanuncommonandchallengingdisease;itdiffersfromadultdetachmentsinetiology,anatomicalcharacteristics,managementandprognosis.PRDscanbeparticularlychallenging,evenforthemostexpertpaediatricsurgeonsduetothehigherprevalenceoftotalretinaldetachments,latediagnosisandbilateralinvolvementwithrespecttothosewhichoccurinadulthood.Moreover,theanatomicalsuccess,whenachieved,isfrequentlynotrelatedtoafunctionalrecover.Postsurgicaladverseevents,refractiveerrorsandamblyopiamayadditionallyunderminethefinaloutcome.Uptodatetherearefewreviewsregardingtheapproachofretinaldetachmentinchildren,mainlydealingwithrhegmatogenousretinaldetachment.Inthisreview,rhegmatogenous,retinopathyofprematurityrelatedandCoats'-relatedPRDswereconsidered.Theavailableliteraturefromthelastdecadeswerereviewedandsummarized.Epidemiology,etiologyandclinicalpresentation,togetherwiththerapeuticapproachesandoutcomeshavebeenreviewedanddiscussed.

简介：

简介：AIM:Toreviewpublishedclinicalstudiesexaminingtheeffectofnatamycininthetreatmentoffungalkeratitis.METHODS:WeselectedthepublicationsinCENTRAL,MEDLINE,EMBASE,CNKI,andCBM.Thisstudysystematicallyreviewedpublishedrandomizedcontrolledtrials(RCTs)thatcomparednatamycintootherantifungalagents,andconductedfeasibleMeta-analysisofefficacyresultsusingRevman5.2software.RESULTS:WeincludedseventrialswhichweremainlycarriedoutindevelopingcountriesofAsia,withfivetrialsconductedinIndia,oneeachinChinaandBangladesh.Atotalof804participantswererandomizedtofollowingcomparisons:2%econazoleversus5%natamycinshowedlittledifferenceintheeffectsoftreatmentoffungalkeratitis[RR=0.99,95%confidenceinterval(CI),0.8to1.21];chlorhexidinegluconateversus5%natamycinindicatedthattheresultsonhealingoftheulcerat21dwaslessconclusive(RR=0.77,95%CI,0.55to1.08;I2=0%);1%voriconazoleversus5%natamycinsuggestedthatnatamycintreatmentappearedtobesignificantlybetteroutcomesthanvoriconazole(regressioncoefficient=-0.18logMAR;95%CI,-0.30to-0.05;P=0.006),especiallyinFusariumcases(regressioncoefficient=-0.41logMAR;95%CI,-0.61to-0.20;P<0.001);natamycinversusfluconazoleshowedasignificantdifferenceincurerate(χ2=5.048,P<0.05)andnatamycingroupwasmoreeffectivethanfluconazoleinaverageperiodoftherapy(t=7.94,P<0.01).CONCLUSION:Natamycinwasapreferablechoiceinthetreatmentoffungalkeratitis,especiallyintheearlyperiodofFusariumcases.

简介：Theaimofthismanuscriptistoreviewtheactionandadverseeffectsofcombinedoralcontraceptives(COCs)onoculartissues.Thepercentageofunwantedpregnanciesandthesubsequentabortionsmakecontraceptioncrucialworldwide.Over100millionwomenaroundtheworldusecommoncontraceptivemethods,includingintrauterinedevices,combinedestrogenandprogestinoralcontraceptives,aswellasprogestinonlypreparations(oralcontraceptives,implantsorinjections).COCsarewidelyusedforcontraception,buttheyarealsoindicatedinmenorrhagia,endometriosis,acneandhirsutism,fibroiduterusandpremenstrualsyndrome.However,theyhavebeenassociatedwithhighratesofcardiovascularevents,venousthromboembolicdisease,ischemicstrokesandbreastcancer.TheincidenceofCOCs-relatedocularcomplicationsisestimatedtobe1in230000,includingdryeyesymptoms,cornealedema,lensopacitiesandretinalneuro-ophthalmologicorvascularcomplications.WemayinferthattheseriousocularcomplicationsofCOCscanbepreventedbyeliminatingtheestrogendosageandchoosingthird-generationprogestins.Inanycase,doctorsshouldtakeintoconsiderationthesystemicandocularhistoryofthepatientsbeforeselectinganymethodofcontraception.

简介：AIM:Toestimateoverallprevalenceofretinopathyofprematurity(ROP)inIranusingasystematicreviewandMeta-analysis.METHODS:AsystematicreviewandMeta-analysiswasperformedofallpublishedstudiespertainingtoprevalenceofROPusinginternationalandnationalelectronicdatabases(ISIWebofSciences,PubMed,Scopus,GoogleScholar,SID,MagIran,andIranMedex)fromtheirinceptionuntilMay2016withstandardkeywords.BeggandEggertestswereusedtoexaminethepublicationbiasandCochrantestandI~2statisticswereusedtoevaluatethestatisticalheterogeneity.PooledestimateoftheprevalenceofROPwerecalculatedusingrandomeffectsMetaanalysis.RESULTS:ThepublicationbiasassumptionwasrejectedbyEggertestswithP-valueequalto0.024.TheresultsofCochrantestandI~2statisticsrevealedsubstantialheterogeneity(Q=1099.02,df=25,I~2=97.7%,P=0.001).TheoverallprevalenceofROPusingtherandomeffectmodelinIranwas26.1%(95%CI:20.3%-31.8%).CONCLUSION:TheprevalenceofROPisrelativelyhighinIran.Lowbirthweightandgestationalagearesignificantriskfactorsforthedisease.Improvedcare,includingoxygendeliveryandmonitoring,forpretermbabiesinallfacilitysettingswouldreducethenumberofbabiesaffectedwithROP.

简介：AIM:ToperformaMeta-analysistoexplorethecorrelationbetweenmetabolicsyndromeandintraocularpressure(IOP).METHODS:WesearchedPubMedandEmbaseinNovember2017forstudiesdiscussingtherelationshipbetweenmetabolicsyndromecomponentsandIOPinpatients.Pearsoncorrelationcoefficients,oddsratiosandstandardizedbetaswereextractedfrominclusivestudies.Heterogeneityandpublicationbiaswerechecked.RESULTS:Of295articles,10metinclusioncriteriaandprovidedsufficientdataforMeta-analysis.ResultsshowedasignificantpositiverelationbetweenmetabolicsyndromeandIOP(Z=0.47,95%CI:0.15-0.79,P=0.005).Thefivecomponents[waistcircumference,hypertriglyceridemia,highbloodpressure,highfastingglucoseandlowhighdensitylipoprotein(HDL)-cholesterol]ofmetabolicsyndromeallshowedpositivecorrelationwithIOPexceptthelowHDL-cholesterolwhichhadnostatisticalsignificance.ThepooledZwas0.08(95%CI:0.04-0.12),0.16(95%CI:0.11-0.21),0.16(95%CI:0.10-0.22),0.30(95%CI:0.20-0.40)and0.12(95%CI:0.08-0.16),respectively.Begg’stestandEgger’stestshowednoevidenceofsignificantpublicationbiasofthisMeta-analysis.CONCLUSION:OurfindingssuggestthatmetabolicsyndromeanditscomponentsaresignificantlyassociatedwithIOP,besidestheHDL-cholesterol.ThisassociationmaybeusedtocontrolIOPbyinterveningtheoccurrenceofmetabolicsyndrome.

简介：AIM:Tocomparetheeffectivenessandsafetybetweenbevacizumabandranibizumabinthetreatmentofagerelatedmaculardegeneration(AMD)throughasystematicreviewandmeta-analysis.METHODS:Weperformedacomprehensivesearchofrandomizedcontrolledtrials(RCTs),non-RCTs,casecontrolandcohortstudiesthatcomparedbevacizumabandranibizumabusingPubMedandtheCochraneLibrary.Aftertherelateddatawereextractedbytwoinvestigatorsindependently,pooledweightedmeandifferences(WMDs)andriskratios(RRs)with95%confidenceintervals(CIs)wereestimatedusingarandom-effectsorafixed-effectsmodel.RESULTS:AtotaloffourRCTsinvolving1927patientsandelevenretrospectivecaseseriesinvolving2296patientswereincluded.Fortheprimaryoutcomes,nosignificantdifferenceswerefoundbetweenranibizumabgroupandbevacizumabgroupinvisualacuity(WMD:-0.04;95%CI:-0.08to0.00;P=0.06),bestcorrectedvisualacuity(WMD:-0.05;95%CI:-0.10to0.00;P=0.05),retinathickness(WMD:-4.69;95%CI:-13.15to3.76;P=0.86)andfovealthickness(WMD:10.91;95%CI:-14.73to36.56;P=0.40).Thepooledanalysesintheevaluationofsafetyshowedthatcomparedtobevacizumab,ranibizumabwasassociatedwithdecreasedrisksofocularinflammation(RR:0.45;95%CI:0.23to0.89;P=0.02)andvenousthromboticevents(RR:0.27;95%CI:0.08to0.89;P=0.03).However,therewerenosignificantdifferencesobservedindeaths(P=0.69)andarterialthromboembolicevents(P=0.71)betweenthetwogroups.CONCLUSION:Withequalclinicalefficacy,ranibizumabwasfoundtobeassociatedwithlessadverseeventscomparedtobevacizumab,indicatingthatranibizumabmightbeasafermanagement.

简介：AIM:ToconductaMeta-analysisforinvestigatingthevariationsinintraocularpressure(IOP)andcentralcornealthickness(CCT)duringnormalpregnancy.METHODS:WesearchedforclinicaltrialspublisheduptoNovember2015withoutlanguageorregionrestrictionsinPubMed,EMBASE,WebofScience,theCochraneCentralRegisterofControlledTrials,Ovid,EBSCO,Elsevier,theChineseBiomedicineDatabase,WanFang,CNKI,CQVIPandGoogleScholar.Studiesoftheocularchangesobservedinpregnantwomenwereselected.ThemainoutcomeswereassessedbychangesinIOPandCCT.RESULTS:Fifteenstudieswereincluded.Insubgroupanalyses,IOPwassignificantlydecreasedduringthesecondMD=-1.53,95%CI(-2.19,-0.87);P<0.00001,andthirdMD=-2.91,95%CI(-3.74,-2.08);P<0.00001trimestersofpregnancy.CCTwasincreasedduringthesecondMD=10.12,95%CI(2.01,18.22);P=0.01,trimesterofpregnancy;moreover,duringthethirdtrimesterofpregnancy,theCCTdisplayedanincreasingtrend,butthedifferencewasnotsignificantMD=5.98,95%CI(-1.11,13.07);P=0.1.CONCLUSION:AdecreaseinIOPisaccompaniedbyanincreaseinCCTinthesecondandthirdtrimestersofanormalpregnancyinwomen.

简介：AIM:Toreportthecytologyresultsof25-gaugetransconjunctival(25G-TSV)diagnosticvitrectomyincasessuspiciousforintraocularlymphoma(IOL),andcomparetheresultstothosereportedintheliterature.METHODS:Clinicalandcytopathologicalrecordsof18vitreousbiopsyspecimensobtainedvia25G-TSVdiagnosticvitrectomyin12patientssuspiciousforIOLwerereviewedretrospectively.Areviewoftheliteratureinregardstothediagnosticyieldsofvitreousspecimensobtainedvia25-gaugeand20-gaugediagnosticvitrectomyinsuspectedcasesofIOLwasperformed.RESULTS:Eighteeneyesfrom12patientswithclinicalsuspicionofIOLunderwentdiagnostic25G-TSV.ThecytopathologicalinvestigationsdemonstratedIOLin15eyes(83.3%).Vitreousanalysiswasnon-diagnosticin3eyes(16.7%).CONCLUSION:Twenty-five-gaugediagnosticvitrectomyyieldsadequatesampleforcytologicalevaluationofthevitreousincasessuspiciousforIOL.Thediagnosticresultsofthe25G-TSVinthecurrentstudyaresuperiortothosereportedfor20-gaugevitrectomybutequivalenttothosereportedfor25G-TSVinthepublishedliterature.

简介：AIMTo系统地基于快速的培植和trabeculectomy(Trab)的功效和费用考察当前的证据因为不受管束的glaucoma.METHODSClinical审判被电子数据库(PubMed，EMBASE，科学的ISI网和Cochrane图书馆)识别，并且数据例如intraocular压力(IOP)，完全、合格的成功率，手术后的复杂并发症和费用，是从这些相关研究的exacted。加权的吝啬的差别(WMD)，机会比率(或)并且95%信心间隔(CI)用相关出版物和二篇摘要遇见了的随机效果的model.RESULTSEleven被计算并且被分享包括标准。快车的功效在1点类似于在IOP减小(IOPR%)的百分比的Trab的，2y(WMD：-2.01；95%CI：-7.92-3.90；P=0.50和WMD：2.89；95%CI：-8.05-13.83；P=0.60，分别地)。快车拥有了重要更高完全、合格的成功率(或：1.59；95%CI：1.07-2.35；P=0.02并且或：1.74；95%CI：1.06-2.86；P=0.03，分别地)。而且，快车比Trab施加了hypotony和hyphema的显著地更低的频率(或：0.39；95%CI：0.21-0.72；P=0.003并且或：0.27；95%CI：0.10-0.69；P=0.003，分别地)。然而，根据以前的三studies.CONCLUSIONBothTrab和快车在二个组之间的费用上没有一致结果在阴沉的IOP有相等的功效，还快速比Trab有hypotony和hyphema的更低的风险。不过，快车的费用是否是不到Trab的应该进一步被调查长远来说保证基于证据的结论。

简介：AIM:Tocomparetheefficacyandsafetyofcombinationofranibizumabwithphotodynamictherapy(PDT)vsranibizumabmonotherapyinthetreatmentofage-relatedmaculardegeneration(AMD).METHODS:TheCochraneCentralRegisterofControlledTrials(CENTRAL)intheCochraneLibrary,Pubmed,andEmbaseweresearched.Therewerenolanguageordatarestrictionsinthesearchfortrials.Onlyrandomizedcontrolledtrials(RCTs)wereincluded.MethodologicalqualityoftheliteratureswasevaluatedaccordingtotheJadadScore.RevMan5.2.6softwarewasusedtodothemeta-analysis.RESULTS:Sevenstudieswereincludedinoursystematicreview,amongwhichfourofthemwereincludedinquantitativeanalysis.Theresultshowsthattheranibizumabmonotherapygrouphadabettermeanbestcorrectedvisualacuity(BCVA)changevsbaselineatmonth12comparedwiththatofthecombinationtreatmentgroup,andthestatisticaldifferencewassignificant(WMD,-2.61;95%CI,-5.08to-0.13;P=0.04).However,aftertheremovalofonestudy,thedifferencebetweenthetwogroupsshowednosignificantdifference(WMD,-2.29;95%CI,-4.81to0.23;P=0.07).Meanwhile,nosignificantcentralretinalthickness(CRT)reductionwasfoundinthecombinationtreatmentgroupandtheranibizumabmonotherapygroupat12monthsfollow-up.Nevertheless,thecombinationgrouptendedtohaveagreaterreductioninCRT(WMD,-4.13μm;95%CI,-25.88to17.63,P=0.71).Theproportionofpatientsgainingmorethan3linesatmonth12intheranibizumabgroupwashigherthaninthecombinationgroupandtherewasasignificantdifference(RR,0.72;95%CI,0.54to0.95;P=0.02).Whereastherewasnosignificantdifferencefortheproportionofpatientsgainingmorethan0lineatmonth12betweenthetwogroups(RR,0.93;95%CI,0.76to1.15;P=0.52).Thegeneraltendencyshowsareductioninranibizumabretreatmentnumberinthecombinationtreatmentgroupcomparedwiththeranibizumabmonotherapygroup.Asmajoradverseevents,thedifferencesinthenumberofeyepain,endophthalmitis,hypertensionandarterialt